A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Nitric oxide (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases; Pulmonary hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms REBUILD
- Sponsors Bellerophon Therapeutics
- 25 Jul 2023 Status changed from active, no longer recruiting to discontinued. The trial did not meet its primary endpoint, hence was terminated due to futility.
- 05 Jun 2023 Primary endpoint has not been met. (Change in Moderate to Vigorous Physical Activity (MVPA) as Measured by Actigraphy), according to a Bellerophon Therapeutics media release.
- 05 Jun 2023 Results presented in a Bellerophon Therapeutics media release.